Michael Krychman, MD
Obstetrics & Gynecology · Costa Mesa, CANPI 1982689725
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $395,913 of the $546,945 with a category attached, or 72.4%. Exeltis, USA Inc. accounts for 71.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $225,669 and has fallen 79.5% since, to $46,200 in 2025. Among obstetrics & gynecology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $1536.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$389K
- Therapeuticsmd, Inc.$86K
- Scynexis, Inc.$18K
- Lupin Inc.$16K
- Astellas Pharma US Inc$14K
- Coopersurgical, Inc.$8K
- plus $16K from 10 others
What the payments were for
- Consulting fees$395,91372%
- Speaking & faculty fees$121,79722%
- Travel & lodging$22,6904%
- Food & beverage$6,2731%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 89 | $389,123 |
| Therapeuticsmd, Inc. | 154 | $86,009 |
| Scynexis, Inc. | 25 | $18,450 |
| Lupin Inc. | 28 | $15,918 |
| Astellas Pharma US Inc | 13 | $14,188 |
| Coopersurgical, Inc. | 8 | $7,511 |
| AMAG Pharmaceuticals, Inc. | 17 | $6,122 |
| Duchesnay USA Incorporated | 9 | $4,354 |
| Evofem Biosciences, Inc. | 4 | $3,100 |
| Ferring Pharmaceuticals Inc. | 2 | $1,824 |
| Sumitomo Pharma America, Inc. | 1 | $99 |
| GSK | 1 | $74 |
| Pfizer | 2 | $65 |
| Hologic Sales And Service, LLC | 1 | $46 |
| AbbVie | 1 | $40 |
| Myovant Sciences Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$546,945 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeozahFezolinetant | 13 | $8,810 |
| Estradiol (Twice Weekly)Estradiol | 60 | $3,973 |
| ImvexxyEstradiol | 11 | $3,075 |
| DottiEstradiol | 16 | $1,654 |
| YuvafemEstradiol | 13 | $1,474 |
| Estradiol | 21 | $1,273 |
| ProgesteroneProgesterone, Micronized | 24 | $590 |
| Gabapentin | 20 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncVeozah | $14,188 | $8,81013 claims |
| Therapeuticsmd, Inc.Imvexxy | $86,009 | $3,07511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Other obstetrics & gynecology in Costa Mesa
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
- Marc WinterLaguna Hills$399K
- Edward TangchitnobWest Covina$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.